.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Teva
McKinsey
Healthtrust
QuintilesIMS
Baxter
Novartis
Accenture
Cipla

Generated: September 25, 2017

DrugPatentWatch Database Preview

Topotecan hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for topotecan hydrochloride and what is the scope of topotecan hydrochloride patent protection?

Topotecan hydrochloride
is the generic ingredient in three branded drugs marketed by Sun Pharm Inds Ltd, Accord Hlthcare, Actavis Totowa, Mylan Labs Ltd, Teva Pharms Usa, Ingenus Pharms Llc, Chem Werth Inc, Novartis Pharms Corp, Fresenius Kabi Oncol, Hospira Inc, Sagent Pharms, Fresenius Kabi Usa, Dr Reddys Labs Ltd, Cipla Ltd, and Sandoz Inc, and is included in seventeen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Topotecan hydrochloride has eighteen patent family members in sixteen countries.

There are ten drug master file entries for topotecan hydrochloride. Fourteen suppliers are listed for this compound.

Summary for Generic Name: topotecan hydrochloride

Tradenames:3
Patents:1
Applicants:15
NDAs:17
Drug Master File Entries: see list10
Suppliers / Packagers: see list14
Bulk Api Vendors: see list57
Clinical Trials: see list2,576
Patent Applications: see list6,782
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:topotecan hydrochloride at DailyMed

Pharmacology for Ingredient: topotecan hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chem Werth Inc
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION201166-001Aug 8, 2012APRXNoNo► Subscribe► Subscribe► Subscribe
Actavis Totowa
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION090620-001Dec 2, 2010APRXNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-001Oct 11, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Usa
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
SOLUTION;INTRAVENOUS022453-001Dec 20, 2012APRXNoNo► Subscribe► Subscribe► Subscribe
Hospira Inc
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
SOLUTION;INTRAVENOUS200582-001Feb 2, 2011APRXYesYes► Subscribe► Subscribe► Subscribe
Sagent Pharms
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION091284-001Jan 26, 2011APRXNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-002Oct 11, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Dr Reddys Labs Ltd
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION201191-001Mar 9, 2011APRXNoNo► Subscribe► Subscribe► Subscribe
Cipla Ltd
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION091199-001Dec 1, 2010APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
TOPOTECAN
topotecan hydrochloride
SOLUTION;INTRAVENOUS200199-002Feb 25, 2011DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: topotecan hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
INJECTABLE;INJECTION020671-001May 28, 1996► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-002Oct 11, 2007► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-001Oct 11, 2007► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
INJECTABLE;INJECTION020671-001May 28, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: topotecan hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,754,733Crystalline topotecan hydrochloride product and process for making the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: topotecan hydrochloride

Country Document Number Estimated Expiration
South Africa200603508► Subscribe
BrazilPI0416366► Subscribe
Iceland8491► Subscribe
South Korea20060122847► Subscribe
Morocco28179► Subscribe
Japan2007510751► Subscribe
Russian Federation2006120422► Subscribe
Russian Federation2352572► Subscribe
TaiwanI333492► Subscribe
World Intellectual Property Organization (WIPO)2005046608► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TOPOTECAN HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1997Austria► SubscribePRODUCT NAME: TOPOTECAN; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 EU/1/96/027/002 19961112; FIRST REGISTRATION: LI 53857 01 19961016
C0009Belgium► SubscribePRODUCT NAME: TOPOTECAN HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 19961112 ; FIRST REGISTRATION: CH 53857 19961016
C/GB96/057United Kingdom► SubscribePRODUCT NAME: TOPOTECAN; REGISTERED: CH IKS-NR:53857 19961016; UK EU/1/96/027/001 19961112; UK EU/1/96/027/002 19961112
70017Netherlands► SubscribePRODUCT NAME: TOPOTECAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, HYDRAAT OF SOLVAAT, IN HET BIJZONDER HET HYDROCHLORI DE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 - EU/1/96/027/002 19961112; FIRST REGISTRATION: CH IKS 53857 19961016
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
US Army
Argus Health
Federal Trade Commission
Fish and Richardson
Cerilliant
Queensland Health
Farmers Insurance
Chubb
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot